UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Finance receivable interest income, including fees	$ 6,828	$ 11,805	$ 17,243	$ 20,484
Pharmaceutical development	114	10,461	350	10,659
Other			480	496
Total revenues	6,942	22,266	18,073	31,639
Costs and expenses:
Interest expense	80	94	160	239
Pharmaceutical manufacturing, research and development expense	1,480	1,542	3,381	3,090
Change in fair value of acquisition-related contingent consideration		(147)		(147)
Depreciation and amortization expense	626	811	1,330	2,493
General and administrative	3,018	3,360	6,178	6,245
Income from operations	1,738	16,606	7,024	19,719
Other (expense) income, net
Unrealized net (loss) gain on derivatives	(472)	609	(1,165)	892
Unrealized net (loss) gain on equity securities	(519)	283	(547)	1,215
Income before income tax expense	747	17,498	5,312	21,826
Income tax expense	182	3,528	1,269	4,467
Net income	$ 565	$ 13,970	$ 4,043	$ 17,359
Net income per share
Basic	$ 0.04	$ 1.09	$ 0.32	$ 1.36
Diluted	$ 0.04	$ 1.09	$ 0.31	$ 1.35
Weighted average shares outstanding
Basic	12,835,000	12,796,000	12,833,000	12,794,000
Diluted	12,885,000	12,834,000	12,882,000	12,822,000